@article {UcsularPA3271, author = {Fatma Demirci Ucsular and G{\"u}listan Karadeniz and G{\"u}lru Polat and Aysu Ayranc{\i} and Enver Yaln{\i}z and Filiz G{\"u}ldaval and Melih B{\"u}y{\"u}k{\c s}irin and Ceyda Anar}, title = {Clinical differences between elderly and nonelderly patients with COVID-19}, volume = {58}, number = {suppl 65}, elocation-id = {PA3271}, year = {2021}, doi = {10.1183/13993003.congress-2021.PA3271}, publisher = {European Respiratory Society}, abstract = {Objective: In our study, we aimed to examine the characteristics of COVID-19 disease, disease severity, comorbidities and mortality rates in elderly patients compared with non-elderly patients.Methods: Patients(n:469) who were followed up in outpatient, inpatient and intensive care units with the diagnosis of COVID-19 between 11 March 2020 - 01 June 2020 were retrospectively included in the study. Two groups of patients were formed, namely the elderly group (>=65 years, n:101) and non-elderly (\<65 years, n:368).Results: When compared to the non-elderly group; The incidence of severe pneumonia (31\% / 12.6\%) and critical illness (16\% / 5.8\%), comorbidity (85\% /\% 37.2), hospitalization time (8/5 days) were significantly higher in the elderly group ( p \<0.05). 23 (22.8\%) of elderly patients and 27 (7.3\%) of non-elderly patients died (p = 0.000). It was seen that mortality increased 3.5 times in elderly patients compared to Nonelderly group. Expected survival time; It was 145.85 days (CI 95\% = 133-158.66) in the elderly age group and 170.36 days (CI 95\% = 166-174.6) in the non-elderly age group (p \<0.000) (Figure 1). In ROC analysis; In predicting mortality, the sensitivity of age was 86\% (73.3-94.2), specificity was 66.83\% (62.1-71.3), cut-off\> 56 (AUC = 0.775; p \<0.001).Measurements and Main Results: In elderly patients diagnosed with COVID-19, mortality is high, comorbidities are more frequent, and the disease is more severe. Age\> 56 can be used to predict cut-off mortality.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3271.This abstract was presented at the 2021 ERS International Congress, in session {\textquotedblleft}Prediction of exacerbations in patients with COPD{\textquotedblright}.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/58/suppl_65/PA3271}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }